Abstract
It is reported that the usage of high-dose intravenous immunoglobulin (HD-IVIG) in systemic autoimmune iseases is associated with various adverse events in a wide range of severity. We aimed to investigate the frequency and profile of adverse events in a group of patients with diffuse connective tissue diseases and Wegener’s granulomatosis (WG) who were administrated HD-IVIG for different indications. We recorded the data of 38 patients (25 females and 13 males) aged 38 ± 15 (12–75) years who were followed up with the diagnosis of systemic autoimmune diseases between 1994 and 2006 according to a predefined protocol. Patients with active disease were treated with HD-IVIG and standard immunosuppressives concomitantly. We evaluated the occurrence of allergy, acute renal failure, thromboembolic events, neutropenia, hemolytic anemia, aseptic meningitis, and vasculitis during infusion therapy of HD-IVIG and in the following 3 weeks. We commenced a total of 130 infusions of HD-IVIG. Patients were administrated 1–12 (3.4 ± 2.6) infusions of HD-IVIG as needed. Indications for HD-IVIG were unresponsiveness or partial response to standard treatment, severe infections along with disease activity, and severe thrombocytopenia in the preoperative period in 97, 23, and 5% of patients, respectively. Minor adverse events were seen in two patients during HD-IVIG infusions. One patient with WG developed rapidly progressive renal failure during severe disease flare between HD-IVIG infusions. Another patient with WG developed recurrence of deep-vein thrombosis during severe disease flare 3 months after HD-IVIG. Both events were attributed to severe disease activity. Adverse events like allergy, acute renal failure, thromboembolic events, hematological problems, aseptic meningitis, and vasculitis are reported in different frequencies (1–81%) in patients who were administered HD-IVIG for systemic autoimmune diseases. HD-IVIG is considered a safe treatment in selected patients assuring adequate infusion precautions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kamali S, Cefle A, Sayarlioglu M, Gul A, Inanc M, Ocal L et al (2005) Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int 25:211–214
Imbach P, Wagner H, Berchtold W, Gaedicke G, Hirt A, Joller P et al (1985) Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2:464–468
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treament of acute Kawasaki syndrome. N Engl J Med 324:1633–1639
Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486
Orbach H, Katz U, Sherer Y, Schoenfeld Y (2005) Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29:173
Schiavotto C, Ruggeri M, Rodeghiero F (1993) Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 78(6 Suppl 2):35–40
Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107
Dalakas MC (1988) A classification of polymyositis and dermatomyositis. In: Dalakas MC (ed) Polymyositis and dermatomyositis. Butterworth, Boston, pp 1–16
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311
Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB et al (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44(4):912–920
Katz U, Shoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14(10):802–808
Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC et al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142(8):620–626
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tufan, F., Kamali, S., Erer, B. et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol 26, 1913–1915 (2007). https://doi.org/10.1007/s10067-007-0694-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0694-y